Danish pharmaceutical company ALK-Abelló A/S (CPH:ALK-B) announced on Monday the start of Phase I clinical development of its investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy.
Conducted in North America, the trial will assess the tolerability and safety of an up-dosing regimen with a once-daily peanut SLIT tablet.
This follows the successful completion of a feasibility study in late 2021, which confirmed that the same technology used in ALK's SLIT tablets for respiratory allergies was also suitable for use in the peanut SLIT tablet.
Approximately 100 adults, adolescents and children with a confirmed peanut allergy will participate in the trial, which is expected to involve up to 15 centres. The trial is scheduled to be completed in 2023.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients